Rendement sur 1 an (CAGR)
-7.89%
Sanofi SA Exchange (PA, EUR)
SAN.PA
71.79
-1.01 (-1.38%)
HealthcareDrug Manufacturers - General
Loading...
Rendement sur 3 ans (CAGR)
-10.98%
Rendement sur 5 ans (CAGR)
-3.16%
Rendement sur 10 ans (CAGR)
-0.63%
Analyse boursière d'Objective Corporation – État au sein de l'État
Lire plusCapitalisation boursière
86.38B
Cours/chiffre d'affaires
1.80
Valeur d'entreprise
139.52B
Cours/valeur comptable
1.24
Rendement du div
0.00%
Années de croissance
-
Croissance du div
-
Versement FCF
62.02%
Trailing P/E
12.78
PEG
-
P/E prévisionnel
7.95
Croissance EPS
-8.21%
Informations sur les actions
Qu'est-ce qu'une bourse ? Fonctionnement, acteurs, exemples
Lire plusGraphique boursier
Loading...
Données du prix des actions
| Ouverture | 73.22 |
| Max journalier | 73.56 |
| Min journalier | 72.10 |
| Volume journalier | 2.17M |
| Niveau record | 109.62 |
| Estimation des analystes sur 1 an | 94.28 |
| Beta | 0.28 |
| EPS (TTM) | 5.65 |
| Dividende par action | 0.00 |
| Date ex-div | 5 May 2026 |
| Prochaine date de bénéfices | 23 Apr 2026 |
Potentiel de baisse
Loading...
Données du potentiel de baisse
| SAN.PA | S&P500 | |
| Baisse de prix actuelle par rapport au niveau record | -34.51% | -0.84% |
| Baisse de prix actuelle la plus importante | -55.80% | -56.47% |
| Date de la baisse la plus importante | 10 Oct 2008 | 9 Mar 2009 |
| Baisse moyenne par rapport au record | -19.75% | -10.68% |
| Délai moyen pour nouveau record | 44 days | 12 days |
| Délai max pour nouveau record | 2908 days | 1805 days |
Actualite
Britain’s biggest pharmaceutical companies have warned the future of the industry is at risk as Europe loses ground to the US and China in medical research.
22 septembre 2026
SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.
25 septembre 2026
Sanofi (ENXTPA:SAN) opened the Charles Best Building in Canada, described as the largest biomanufacturing investment in the country. The new Canadian site expands Sanofi's flu vaccine production capac...
23 septembre 2026
European equities traded in the US as American depositary receipts were tracking lower Wednesday mor
23 septembre 2026
All the chairs of Europe’s big pharma companies have written a public letter asserting that a shift in strategy is needed to close the gap to international rivals.
23 septembre 2026
The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.
22 septembre 2026
Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.
22 septembre 2026
Sanofi (NASDAQ:SNY) is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research output under new leadership, Chief Scientific Officer and Globa...
22 septembre 2026
Orphan drug demand is rising as genomics, biologics and personalized therapies advance, aided by faster approvals, government incentives, advocacy and improved rare-disease diagnosis.Dublin, Sept. 22,...
22 septembre 2026
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s Global Healthcare Conference, with CEO and President Najat Khan emphasizin...
21 septembre 2026